血清HE4和CA125对卵巢癌和盆腔良性疾病的鉴别诊断价值

Comparison of Clinical Values of Serum Human Epididymal Protein 4 and Carbohydrate Antigen 125 for Differential Diagnosis of Ovarian Cancer and Benign Pelvic Disease

目的比较人附睾蛋白4(HE4)和糖链抗原125(CA125)对卵巢癌和盆腔良性疾病鉴别诊断的临床价值。方法用化学发光免疫分析法测定75例卵巢癌和80例盆腔良性疾病患者血清HE4和CA125水平。结果卵巢癌患者血清HE4和CA125水平显著高于盆腔良性疾病患者,差异有统计学意义(P<0.05)。血清HE4对卵巢癌的灵敏度(SEN)、特异度(SPE)和准确度分别为70.7%、91.3%和81.3%,血清CA125对卵巢癌的SEN、SPE和准确度分别为78.7%、81.3%和80.0%,血清HE4+CA125并联试验对卵巢癌的SEN、SPE和准确度分别为88.0%、78.8%和83.2%。HE4对Ⅰ期卵巢癌的灵敏度显著高于CA125,差异有统计学意义(P<0.05)。结论对卵巢癌和盆腔良性疾病的鉴别诊断,血清HE4优于CA125。

Objective To compare the clinical values of serum human epididymal protein 4（HE4）and carbohydrate anti-gen 125（CA125）for differential diagnosis of ovarian cancer and benign pelvic disease. Methods The levels of serum HE4 and CA125 were measured in 75 patients with ovarian cancer and 80 patients with benign pelvic disease. Results The levels of HE4 and CA125 were significantly higher in patients with ovarian cancer than those in patients with benign pelvic diseases（P〈0. 05）. In comparison with patients with benign pelvic disease, the diagnosis sensitivity, specificity and accuracy of HE4 were 70. 7%, 91. 3% and 81. 3%, respectively. The diagnosis sensitivity, specificity and accuracy of CA125 were 78. 7%, 81. 3% and 80. 0%, respectively. The diagnosis sensitivity, specificity and accuracy of HE4/CA125 parallel detection were 88. 0%,78. 8% and 83. 2%,respectively. The diagnosis sensitivity of HE4 for ovarian cancer stageⅠwas significantly higher than that of CA125. Con-clusion For differentiation of benign and malignant pelvic mass,HE4 was a better marker than CA125.